ClinicalTrials.gg
RecruitingNCT04133194EASIUpdated Sep 26, 2023

Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis

A Phase 4 interventional study of Mesalazine and Mesalazine in Ulcerative Colitis, sponsored by Flemming Bendtsen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Flemming Bendtsen · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing mesalamine in Colitis, Ulcerative — 5 open to participants now, 6 under way, 1 of them phase 3. Mesalamine · Colitis, Ulcerative.

Planned enrollment
26th of 49
200 · median 206
Started
2019
the only one that year
Phase 4
13 of 50
3 open now
Registered
43rd of 50
by date

Among the 50 studies testing mesalamine in Colitis, Ulcerative, this one is the 26th largest by planned enrollment of the 49 interventional ones that give a count, is the only one that started in 2019, is one of 13 in phase 4, and was the 43rd registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 50 studies testing mesalamine in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About mesalamine

Mesalamine: first FDA approval 1987 (ROWASA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing mesalamine in Colitis, Ulcerative, or all of them as a file.
02

Study summary

Several oral mesalazine (5-ASA) formulations exist, but the regimes require several tablets per day. Such regimens are not ideal and can interfere with normal daily activities of patients. Non-adherence has been associated with an increase in the risk of relapse and worse disease course; leading to a decrease in quality of life, an increase in societal and personal costs, and worst case increases the risk of colorectal cancer. Recently, a new formula for 5-ASA has been approved by the Danish Medicine Agency, with a single tablet regime per day.

Primary purpose:

  • To investigate whether a simplified treatment regimen for 5- ASA (1600 mg as one tablet per day [intervention]) improves adherence with preserved remission rates compared to conventional therapy.

Secondary purposes:

  • Compare levels of endoscopic, mucosal and histological inflammation in predicting risk of relapse between the intervention group and the conventional therapy group.
  • Investigate whether a simplified treatment regimen improves the disease course compared to the conventional therapy.
  • To assess the correlation between different endpoints and the disease courses, with the use of clinical, endoscopic, histological, self-reported and biochemical markers.
  • Improve, correlate and assess patient-reported outcomes in a prospective manner.
  • To establish a biobank of cases with quiescent/mild ulcerative colitis (UC) for identification of future biomarkers.
03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age between and including 18 and 60
  • Diagnosed with UC according to the Copenhagen Diagnostic Criteria
  • Length of disease of max. 10 years
  • Stable remission on 5-ASA (defined as partial Mayo score ≤1) for at least 2 months without need for oral before inclusion.
  • Endoscopic remission defined as Mayo Clinic Endoscopic Score \< 2
  • Have had a relapse within the last 2 years

    • Defined as the need of escalation of treatment or change medical treatment.

Exclusion criteria

Exclusion Criteria:

  • Evidence of infectious diarrhoea (i.e. pathogenic viruses, bacteria or Clostridium difficile toxin in stool culture) within the last month
  • On immunomodulators, including methotrexate
  • On any biological therapy
  • Any previous abdominal surgery related to UC
  • Any chronic infections (e.g. , , )
  • Any severe concomitant cardiovascular, , hematologic, hepatic, renal, endocrine, oncologic or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results
  • Well-founded doubt about the patient's cooperation, e.g., because of addiction to alcohol or drugs in the opinion of the investigators.
  • Participation in another clinical trial within the last 30 days, or simultaneous participation in another clinical trial.
  • Any previous documented allergic reaction to tested the medical drugs
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    1600 mg Asacol (mesalazine)

    1600 mg mesalazine (Asacol) treatment regimen (1 tablet per day) for a year

    Drug: Mesalazine

  • Active comparator
    800 mg Asacol (mesalazine)

    800 mg mesalazine (Asacol) treatment regimen (3 tablets per day) for a year

    Drug: Mesalazine

Interventions

06

What researchers measure

Primary outcomes

  1. Medical Adherence

    Measured by drug accountability log Patients having taken ≥80 % are categorised as adherent

    Time frame: through study completion, an average of 2 year

  2. Medical Adherence

    Measured by "Medical adherence rating scale" (MARS) Medical adherence rating scale is a self-reported medical adherence tool consisting of 5 items scored on a 5 point Likert scale (ranging from 5-25). The scale has been used in several IBD studies and a global score \> 20 indicates a good adherence.

    Time frame: through study completion, an average of 2 year

  3. Medical Adherence

    Measured byf drug accountability log (outcome 1) and "Medical adherence rating scale" (MARS, outcome 2) separately, excl. pregnant and breastfeeding women. Further detail see outcome 1 and 2

    Time frame: through study completion, an average of 2 year

Secondary outcomes

  1. Assessment of disease activity by Mayo Score

    The Mayo Score is composed of 4 items. A score from 0-2 is categorised as remission and 11-12 as severe.

    Time frame: through study completion, an average of 2 year

  2. Assessment of disease activity by the Simple clinical colitis activity index (SCCAI)

    The SCCAI rely solely on clinical assessments. Clinical remission are defined as SCCAI \< 1 and clinical response as a change of at least 1 point.

    Time frame: through study completion, an average of 2 year

  3. Assessment of endoscopic severity by the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

    The UCEIS endoscopic severity on a scale of 1-4. Higher score mean worse disease severity.

    Time frame: through study completion, an average of 2 year

  4. Assessment of endoscopic severity by the Mayo endoscopic score

    The Mayo endoscopic score is scored on a scale of 0-3. Higher score mean worse disease severity.

    Time frame: through study completion, an average of 2 year

  5. Assessment of histological severity by the Geboes score

    The Geboes score is interpreted as such: a higher score means higher disease activity.

    Time frame: through study completion, an average of 2 year

  6. Assessment of histological severity by the Nancy Index

    The Nancy Index are interpreted as such: The grade 4 correspond to severe disease, grade 0 as " absence of significant histological disease".

    Time frame: through study completion, an average of 2 year

  7. Assessment of histological severity by the Robarts Histopathology Index (RHI)

    The RHI are interpreted as such: The score are ranging between 0 (no disease activity) to 33 (severe disease activity).

    Time frame: through study completion, an average of 2 year

  8. Correlation between the different clinical scores

    Comparison, correlation and association between the different endoscopic, histological and disease activity indices. Included will be: Mayo score, Simple clinical colitis activity index (SCCAI), Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Nancy Index, Robarts Histopathology Index (RHI) and the Geboes score (see outcome 4-10).

    Time frame: through study completion, an average of 2 year

  9. Remission - days

    Differences in number of days in remission during the trial

    Time frame: through study completion, an average of 2 year

  10. Relapse - days

    Differences in number of days in relapse during the trial

    Time frame: through study completion, an average of 2 year

  11. Remission and relapse - episodes

    Differences episodes of relapses during the trial

    Time frame: through study completion, an average of 2 year

  12. Changes in quality of life

    Prospective analyses of quality of life using 12-Item Short Form Survey (SF12). The SF12 is measured on a global score from 12-56. Beside a global score, a mental and physical dimension will also be calculated.

    Time frame: through study completion, an average of 2 year

  13. Changes in disease specific quality of life

    Prospective analyses quality of life using the Short inflammatory bowel disease questionnaire (SIBDQ) The SIBDQ is a quality of life (QOL) questionnaire ranging from 10-70. Higher score means better QOL.

    Time frame: through study completion, an average of 2 year

  14. Changes in disability among ulcerative colitis patients

    Prospective analyses of disability using the Inflammatory bowel disease disability index (IBD-DI) The IBD-DI measures the disability among patients with inflammatory bowel disease. Higher scores means worse disability.

    Time frame: through study completion, an average of 2 year

  15. Changes in sleep quality

    Prospective analyses of sleep using the Pittsburgh Sleep Quality Index (PSQI), The PSQI was designed to measure sleep quality and disturbance. A global score \> 5 is considered poor sleep quality.

    Time frame: through study completion, an average of 2 year

  16. Changes in resilience

    Prospective analyses of resilience using the Brief Resilience Scale (BRS) The BRS is designed to measure the ability to bounce back or recover from stressful events. Higher scores means higher resilience.

    Time frame: through study completion, an average of 2 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Dec 2024, 61 months after the start.

Of 48 non-industry phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 66. This study's planned 61 months is close to that.

Counting every sponsor, half of 63 studies reached it within 43 months; a quarter within 25 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2019
First posted
Oct 21, 2019
StartActual
Nov 28, 2019
Primary completionEst.
Dec 31, 2024
CompletionEst.
Mar 1, 2025
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04133194
Lead sponsor
Flemming Bendtsen
Responsible party
Flemming Bendtsen (Professor, Senior doctor, MDSci, Copenhagen University Hospital, Hvidovre) — Sponsor-investigator
First posted
Oct 21, 2019
Start date
Nov 28, 2019
Primary completion
Dec 31, 2024 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
Sep 26, 2023

Study contacts

Flemming Bendtsen, MDSci
Contact
Flemming.Bendtsen@regionh.dk
+45 38623273
Bobby Lo, MD
Contact
bobby.lo@regionh.dk
Flemming Bendtsen, MDSci
principal investigator · Copenhagen University Hospital, Hvidovre

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesalamine

Start the discussion